Bacterial Vaginosis Increased Sti Co-Infection - Jul 30

The Story

Quest Diagnostics reported a national study of 1.5 million women showing patients who tested positive for bacterial vaginosis were over three times more likely to have at least one sexually transmitted infection, and 12% of BV-positive patients had an STI co-infection. The data was published by Quest Diagnostics and distributed by PR Newswire on Jul 30, 2026. The findings put diagnostic testing companies such as $DGX in focus for potential higher screening demand.

Why It Matters For Your Portfolio

• The study analyzed 1.5 million women, giving scale to the finding, which could translate into higher lab testing volume if clinicians increase screening, a potential revenue tailwind for diagnostics providers like $DGX.
• 12% of BV-positive patients had at least one STI, a concrete percentage that suggests more tests per patient and higher per-visit lab utilization, which matters for lab-service margins and throughput.
• BV patients were over three times more likely to have an STI, a large relative increase that could prompt changes in screening practices and drive recurring test orders from clinicians and public-health programs.
• Because the study comes from Quest Diagnostics, investors often watch company commentary and volume trends closely after such announcements, as they can signal sustained demand changes across the diagnostics sector.

The Trade

Who should care: healthcare and diagnostics investors and traders tracking lab-service names should pay attention, especially holders of $DGX. What to watch next: testing volume trends and management commentary in upcoming quarterly reports, and any shifts in screening guidance from clinical groups. Will increased screening show up in the next $DGX quarterly update? Monitor volumes and revenue commentary, as no specific earnings date was provided in the release.